Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Low-Dose ICS Therapy.

ClinicalTrials.gov ID: NCT00603278

Public ClinicalTrials.gov record NCT00603278. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 4:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 250mcg Twice Daily Compared With Placebo for 8 Weeks in Adolescent and Adult Subjects With Persistent Asthma Symptomatic on Low-Dose ICS Therapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.

Study identification

NCT ID
NCT00603278
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
622 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 2007 (Type not available)
Primary completion
Nov 2008 (Actual)
Completion
Nov 2008 (Actual)
Last update posted
Dec 28, 2016

2007 – 2008

United States locations

U.S. sites
95
U.S. states
34
U.S. cities
85
Facility City State ZIP Site status
GSK Investigational Site Phoenix Arizona 85028 —
GSK Investigational Site Fort Smith Arkansas 72903 —
GSK Investigational Site Little Rock Arkansas 72211-3733 —
GSK Investigational Site Fresno California 93720 —
GSK Investigational Site Granada Hills California 91344 —
GSK Investigational Site Huntington Beach California 92647 —
GSK Investigational Site Long Beach California 90806 —
GSK Investigational Site Long Beach California 90808 —
GSK Investigational Site Los Angeles California 90048 —
GSK Investigational Site Los Angeles California 90095-1752 —
GSK Investigational Site Palmdale California 93551 —
GSK Investigational Site Riverside California 92506 —
GSK Investigational Site Roseville California 95678 —
GSK Investigational Site San Diego California 92120 —
GSK Investigational Site Torrance California 90505 —
GSK Investigational Site Walnut Creek California 94598 —
GSK Investigational Site West Covina California 91790 —
GSK Investigational Site Colorado Springs Colorado 80910 —
GSK Investigational Site Wheat Ridge Colorado 80033 —
GSK Investigational Site Bridgeport Connecticut 06606 —
GSK Investigational Site Waterbury Connecticut 06708 —
GSK Investigational Site Boca Raton Florida 33487 —
GSK Investigational Site Cocoa Florida 32927 —
GSK Investigational Site Daytona Beach Florida 32114 —
GSK Investigational Site Largo Florida 33770 —
GSK Investigational Site Miami Florida 33126 —
GSK Investigational Site Miami Florida 33157 —
GSK Investigational Site Ocala Florida 34471 —
GSK Investigational Site West Palm Beach Florida 33401 —
GSK Investigational Site Winter Park Florida 32789 —
GSK Investigational Site Gainesville Georgia 30501 —
GSK Investigational Site Bloomingdale/Illinois Illinois 60108 —
GSK Investigational Site Chicago Illinois 60617 —
GSK Investigational Site DeKalb Illinois 60115 —
GSK Investigational Site Gurnee Illinois 60031 —
GSK Investigational Site Evansville Indiana 47713 —
GSK Investigational Site Iowa City Iowa 52240 —
GSK Investigational Site Lenexa Kansas 66215 —
GSK Investigational Site Crescent Springs Kentucky 41017 —
GSK Investigational Site Lexington Kentucky 40536 —
GSK Investigational Site Metairie Louisiana 70002 —
GSK Investigational Site Bangor Maine 04401 —
GSK Investigational Site North Dartmouth Massachusetts 02747 —
GSK Investigational Site Detroit Michigan 48221 —
GSK Investigational Site Taylor Michigan 48180 —
GSK Investigational Site Ypsilanti Michigan 48197 —
GSK Investigational Site Rochester Minnesota 55905 —
GSK Investigational Site Jackson Mississippi 39202 —
GSK Investigational Site Rolla Missouri 65401 —
GSK Investigational Site St Louis Missouri 63141 —
GSK Investigational Site St Louis Missouri 63143 —
GSK Investigational Site Warrensburg Missouri 64093 —
GSK Investigational Site Billings Montana 59101 —
GSK Investigational Site Butte Montana 59701 —
GSK Investigational Site Missoula Montana 59808 —
GSK Investigational Site Las Vegas Nevada 89107 —
GSK Investigational Site Clifton/New Jersey New Jersey 7011 —
GSK Investigational Site Hillsborough New Jersey 08844 —
GSK Investigational Site Red Bank New Jersey 07701 —
GSK Investigational Site Skillman New Jersey 08558 —
GSK Investigational Site East Syracuse New York 13057 —
GSK Investigational Site Ithaca New York 14850 —
GSK Investigational Site Rockville Centre New York 11570 —
GSK Investigational Site The Bronx New York 10461 —
GSK Investigational Site Greensboro North Carolina 27401 —
GSK Investigational Site Greenville North Carolina 27834 —
GSK Investigational Site Raleigh North Carolina 27607 —
GSK Investigational Site Canton Ohio 44718 —
GSK Investigational Site Cincinnati Ohio 45231 —
GSK Investigational Site Cleveland Ohio 44113 —
GSK Investigational Site Columbus Ohio 43235 —
GSK Investigational Site Oklahoma City Oklahoma 73112 —
GSK Investigational Site Oklahoma City Oklahoma 73120 —
GSK Investigational Site Eugene Oregon 97401 —
GSK Investigational Site Medford Oregon 97504 —
GSK Investigational Site Pittsburgh Pennsylvania 15243 —
GSK Investigational Site Bluffton South Carolina 29910 —
GSK Investigational Site Charleston South Carolina 29406 —
GSK Investigational Site Charleston South Carolina 29414 —
GSK Investigational Site Knoxville Tennessee 37909 —
GSK Investigational Site Boerne Texas 78006 —
GSK Investigational Site Dallas Texas 75231 —
GSK Investigational Site Dallas Texas 75246 —
GSK Investigational Site Dickinson Texas 77539 —
GSK Investigational Site Fort Worth Texas 76104 —
GSK Investigational Site Plano Texas 75093 —
GSK Investigational Site San Antonio Texas 78205 —
GSK Investigational Site San Antonio Texas 78229 —
GSK Investigational Site San Antonio Texas 78233 —
GSK Investigational Site Waco Texas 76712 —
GSK Investigational Site South Burlington Vermont 05403 —
GSK Investigational Site Manassas Virginia 22015 —
GSK Investigational Site Bellingham Washington 98225 —
GSK Investigational Site Spokane Washington 99204 —
GSK Investigational Site Spokane Washington 99207 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 60 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00603278, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 28, 2016 · Synced Oct 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00603278 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →